TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05959304

Intervention type: OTHER
Intervention: brolucizumab
Description: There is no treatment allocation. Treatment with brolucizumab 6 mg intravitreal injection will be based on the local label/clinical practice.
Study: NCT05151224

Intervention type: DIAGNOSTIC_TEST
Intervention: microRNA 21
Description: Plasma microRNA 21 5p expression, by real-time polymerase chain reaction, before and after neoadjuvant systemic therapy.~Blood sample will be taken by a trained nurse, amount of blood will be 3 ml, and will be taken twice, one time before the start of the neoadjuvant systemic treatment , second time by the end of the neoadjuvant systemic treatment.
Study: NCT04904380

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active peer learning
Description: HMS, HBS and peer learning in combination with AIR and PRISMS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active peer learning
Description: HMS, HBS and peer learning in combination with AIR and PRISMS
Study: NCT03121066

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Transcranial Magnetic Stimulation
Description: The intervention consists of a 2-week treatment during which TMS will be applied for 10 days (every working day). The stimulation protocol will be intermittent TBS (iTBS). 600 pulses in each area will be applied at intervals of 2 seconds of stimulation and 8 seconds of rest; the total number of pulses per session will be 1200. The stimulation duration is 3 minutes and 12 seconds. This protocol allows the induction of long-term potentiation effects, promoting plasticity in the stimulated areas. To perform the stimulation a 70 mm, figure of 8-coil will be used. In order to precisely locate the stimulated areas a stereotactic image guidance will be used during the stimulation (Brainsight™ 2)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation
Description: The Sham intervention will be carried out using the same stimulation protocol as in the active condition but with the coil rotated 90º to prevent the magnetic field inducing electrical activity in the cortex.
Study: NCT05414149

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: preoperative intravitreal injections of ranibizumab or conbercept
Description: IVR group means patients received intravitreal ranibizumab injections (IVR) (0.5mg/0.05ml) before vitreous surgery. IVC group means patients that received intravitreal conbercept injection (IVC) (0.5mg/0.05ml) before vitreous surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: preoperative intravitreal injections of ranibizumab or conbercept
Description: IVR group means patients received intravitreal ranibizumab injections (IVR) (0.5mg/0.05ml) before vitreous surgery. IVC group means patients that received intravitreal conbercept injection (IVC) (0.5mg/0.05ml) before vitreous surgery.
Study: NCT05475600

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Classical APA group:
Description: Activity type: aerobic Frequency: 3sessions per week Duration of session: 30 to 60min Intensity: mild to moderate (4-6 on RPE Scale) Session description: 1 - Warm-up 5 to 10min / Activation of devices and systems: muscular, articular, cardiovascular / Objective: preparation of body and mind for physical activity. 2 - Training 10 to 30min physical activity with à classical cyclo-ergometer 3 - Cool down 15 to 20min / stretching / Objective: to bring the body back to a resting state

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: APA with Exergaming device
Description: Activity type: aerobic Frequency: 3sessions per week Duration of session: 30 to 60min Intensity: mild to moderate (4-6 on RPE Scale) Session description: 1 - Warm-up 5 to 10min / Activation of devices and systems: muscular, articular, cardiovascular / Objective: preparation of body and mind for physical activity. 2 - Training 10 to 30min physical activity with à classical cyclo-ergometer 3 - Cool down 15 to 20min / stretching / Objective: to bring the body back to a resting state

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: APA associated with biofeedback relaxation
Description: Activity type: aerobic Frequency: 3sessions per week Duration of session: 30 to 60min Intensity: mild to moderate (4-6 on RPE Scale) Session description: 1 - Warm-up 5 to 10min / Activation of devices and systems: muscular, articular, cardiovascular / Objective: preparation of body and mind for physical activity. 2 - Training 10 to 30min physical activity with à Exergaming device 3 - Cool down: 20min / Biofeedback relaxation device / Objective: to bring the body back to a resting state
Study: NCT06530108

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLISSIT model based sexual health education
Description: the PLISSIT model includes the steps of PLISSIT (P-Permission), LI-Limited Information, SS-Specific Suggestions, IT-Intensive Therapy. This model provides communication with the patient and Since it is a model that increases confidence and provides care interventions based on the patient's preference, it has the feature of guiding sexual education during pregnancy by establishing the bond between the pregnant woman and the midwife.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: PLISSIT model based sexual health education
Description: the PLISSIT model includes the steps of PLISSIT (P-Permission), LI-Limited Information, SS-Specific Suggestions, IT-Intensive Therapy. This model provides communication with the patient and Since it is a model that increases confidence and provides care interventions based on the patient's preference, it has the feature of guiding sexual education during pregnancy by establishing the bond between the pregnant woman and the midwife.
Study: NCT05218577

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high selenium functional food
Description: HSFF was made from the liver of the cow, that participant could eat HSFF direcly.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: selenium supplement
Description: 20 microgram/day selenium suppplement powder.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the placebo mocaf powder
Study: NCT06317220

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Administered over 30 minute infusion at MGH main campus
Study: NCT05542446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistin
Description: Visit 1 - screening - Patient selection phase. Patients meeting the eligibility criteria will be screened if not meeting any of the exclusion criteria. A pregnancy test from a urine test will be performed on women of childbearing potential. The patient will be offered participation in the clinical trial and interviewed by the investigator.~Visit 2 (Visit 8, Visit 14 - optional, only if colistin is still indicated) - CMS administration The patient will be hospitalized at FNUSA. CMS will be given intravenously via the central vein catheter (a loading dose of 9 MIU intravenously over 30 minutes followed after 12 hours by a maintenance dose of 4,5 MIU intravenously over 30 minutes every 12 hours; only in patients requiring continuous renal replacement methods will the interval of the maintenance doses be 8 hours).~Visit 3 - Visit 7 (Visit 9-Visit 13, Visit 15-Visit 19 - optional, only if colistin is still indicated) - Pharmacokinetics blood samples collection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colistin
Description: Visit 1 - screening - Patient selection phase. Patients meeting the eligibility criteria will be screened if not meeting any of the exclusion criteria. A pregnancy test from a urine test will be performed on women of childbearing potential. The patient will be offered participation in the clinical trial and interviewed by the investigator.~Visit 2 (Visit 8, Visit 14 - optional, only if colistin is still indicated) - CMS administration The patient will be hospitalized at FNUSA. CMS will be given intravenously via the central vein catheter (a loading dose of 9 MIU intravenously over 30 minutes followed after 12 hours by a maintenance dose of 4,5 MIU intravenously over 30 minutes every 12 hours; only in patients requiring continuous renal replacement methods will the interval of the maintenance doses be 8 hours).~Visit 3 - Visit 7 (Visit 9-Visit 13, Visit 15-Visit 19 - optional, only if colistin is still indicated) - Pharmacokinetics blood samples collection.
Study: NCT05274412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypotension prediction index(HPI)
Description: Implementing hypotension prediction index (HPI) in perioperative goal-directed hemodynamic therapy. Keep HPI \< 85; pulse pressure variation \>12%; keep cardiac index \>2L/min/cm\^2; keep mean arterial pressure \> 65mmHg.
Study: NCT05274412

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ordinary goal-directed hemodynamic therapy
Description: Keep pulse pressure variation \>12%; keep cardiac index \>2L/min/cm\^2; keep mean arterial pressure \> 65mmHg.
Study: NCT05138341

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgical (MIS) intracranial hemorrhage Evacuation
Description: Patients randomized to MIS group will be undergoing an intervention will get Minimal Invasive Surgical treatment.~The market approved Artemis Device (MIS group) will be used. The Artemis Device, Aspiration Pump, and endoscope are used to rinse (irrigate) this area and to gently suction out the rinsing fluid and any blood or clot in brain. The Device is also designed to prevent clogging during the suction of fluid and blood.
Study: NCT05863390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: McKenzie exercise
Description: routine simple McKenzie exercise
Study: NCT06170281

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Migraine Behavioral Treatment
Description: Migraine Behavioral Treatment involving daily activities

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Migraine Behavioral Treatment
Description: Migraine Behavioral Treatment involving daily activities

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Migraine Behavioral Treatment
Description: Migraine Behavioral Treatment involving daily activities

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Migraine Behavioral Treatment
Description: Migraine Behavioral Treatment involving daily activities

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Migraine Behavioral Treatment
Description: Migraine Behavioral Treatment involving daily activities

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Migraine Behavioral Treatment
Description: Migraine Behavioral Treatment involving daily activities
Study: NCT04928391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: A single dose of 0.5 µ/kg IV dexmedetomidine at the end of surgery
Study: NCT05155917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine 300 UNT/ML [Toujeo]
Description: insulin glargine sc (0.25 U/kg body weight)
Study: NCT04928391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: A single dose of 0.1 mg/kg IV nalbuphine at the end of surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: Same volume of saline placebo IV at the end of surgery
Study: NCT05450744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131I-IPA
Description: 131I-IPA: injection/solution administrated intravenously via infusion in ascending doses 18F-FET: injection/solution administrated intravenously
Study: NCT05242978

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: acute single dose nutrition intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: acute single dose nutrition intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: acute single dose nutrition intervention
Study: NCT05863390

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Trochanteric belt
Description: Trochanteric belt with conventional physical therapy
Study: NCT04643366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Neoadjuvant chemotherapy with 2 months of combination oxaliplatin and 5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Pelvic Intensity-modulated radiation therapy (IMRT)
Study: NCT06376188

Intervention type: OTHER
Group type: OTHER
Intervention: communication training
Description: The intervention group received a communication training session prior to the prebriefing and familiarization of the scenario, including advice on how to improve communication skills as well as how to create an optimal setting for difficult medical conversations. This communication training session has been created on the basis of an in-depth literature research.(Brock et al., 2019; Chumpitazi et al., 2016; Collins et al., 2018; Grant et al., 2016; Tobler et al., 2014; Vaidya et al., 1999; Yuan et al., 2019)
Study: NCT05032261

Intervention type: DRUG
Intervention: Circulatory shock with norepinephrine in ICU
Description: Circulatory shock with norepinephrine in ICU

Intervention type: DRUG
Intervention: Circulatory shock with norepinephrine in ICU
Description: Circulatory shock with norepinephrine in ICU
Study: NCT05208008

Intervention type: OTHER
Intervention: With service dog
Description: No intervention
Study: NCT06099366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction: vincristine, L-asparaginase, dexamethasone, intrathecal Ara-C, intrathecal Methotrexate
Description: vincristine 1.5mg/m2 L-asparaginase 6,000U/m2 Dexamethasone 6mg/m2 Intrathecal Cytarabine Intrathecal Methotreate
Study: NCT00663624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspart insulin
Description: subcutaneous aspart insulin every 2 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Usual care as prescribed by the ED physicians.
Description: Usual care can be oral anti-diabetic agents, subcutaneous insulin therapy or a combination of both. Subcutaneous insulin used for usual care could include NPH, 70/30 insulin, aspart insulin, regular insulin or insulin glargine
Study: NCT05950542

Intervention type: DRUG
Intervention: Baricitinib
Description: JAK inhibit0rs
Study: NCT05892497

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Tecartherapy
Description: The tecartherapy intervention was with a deep diathermy machine applied to the patient's lower extremity for 30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tecartherapy
Description: The tecartherapy intervention was with a deep diathermy machine applied to the patient's lower extremity for 30 minutes.
Study: NCT05656560

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical decision support (CDS)-Commitment nudge
Description: EHR clinical decision support alerts-clinician commitment to discuss high risk polypharmacy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical decision support (CDS)-Commitment nudge
Description: EHR clinical decision support alerts-clinician commitment to discuss high risk polypharmacy

Intervention type: OTHER
Group type: OTHER
Intervention: Clinician education
Description: Brief, online education module for primary care clinicians
Study: NCT05809323

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention Group
Description: Patients will be educated on methods of self-evaluating exertion and cardiovascular effort by assessing respiratory rate and perceived exertion. Next, patients will be given options for cardiovascular activities and complete at a moderate level of activity for a minimum of 150 minutes per week. Patients will perform a combination of exercises under the supervision of a physical therapist until a mod intensity level is reached and sustained. Patients will be taught to use the activity tracker to record their heart rate, activity, and PES. Patients will have a phone call every week to assess status, answer questions, and provide guidance on progressing intensity or duration of exercise. At the end of 12 weeks all patients will return for re-assessment.
Study: NCT05536154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Day 1\~Day 2: 75mg/m\^2
Study: NCT05536154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Day 1\~Day 2: 200mg/m\^2, q12h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: Day 6: 6mg
Study: NCT05809323

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Patients in the control group will be instructed to continue with baseline physical activities over the duration of the study and be given instructions on the use of the activity tracker. At the end of 12 weeks all patients will return for re-assessment.
Study: NCT05772442

Intervention type: DIAGNOSTIC_TEST
Intervention: Extra blood samples (5-10 mL) drawn
Description: Extra blood samples will be sent for metabolomics analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Extra blood samples (5-10 mL) drawn
Description: Extra blood samples will be sent for metabolomics analysis.
Study: NCT06197022

Intervention type: DEVICE
Group type: OTHER
Intervention: Mozec™ SEB Sirolimus Eluting Rx PTCA Balloon Dilatation Catheter
Description: Combination of scoring-balloon angioplasty (SBA) plus sirolimus-eluting balloon angioplasty (SEBA) for diffuse (lesion length ≥20 mm), small vessel (diameter 1.5 mm -2.75 mm) coronary disease.
Study: NCT04939779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R)
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R)
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006)
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006)
Description: Oral administration
Study: NCT06124885

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AKI risk screening using RenaFAST POCT test kits
Description: Based on the type and duration of drug therapy, a maximum of 5 time-point urine samples will be collected and real-time biomarker measurement will be done using the RenaFAST POCT kits. Additionally, Trefoil factor 3 (TFF3) biomarker levels will also be quantified using developed POCT kits.~Patients with all 3 biomarker (Clusterin, MCP1 and ß2MG) levels higher than the study cut-off will be identified as high-risk for AKI. The nephrology consultants within the research team will perform a medical chart and physical review (where required) of these patients, detailing potential actions to be taken in research data collection forms. No actual intervention (other than a patient review) will be performed.
Study: NCT00175162

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Osteopal G vs. Refobacin-Palacos R bone cement
Description: Bone cement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Osteopal G vs. Refobacin-Palacos R bone cement
Description: Bone cement
Study: NCT06099366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction: vincristine, L-asparaginase, dexamethasone, intrathecal Ara-C, intrathecal Methotrexate
Description: vincristine 1.5mg/m2 L-asparaginase 6,000U/m2 Dexamethasone 6mg/m2 Intrathecal Cytarabine Intrathecal Methotreate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction: vincristine, L-asparaginase, dexamethasone, intrathecal Ara-C, intrathecal Methotrexate
Description: vincristine 1.5mg/m2 L-asparaginase 6,000U/m2 Dexamethasone 6mg/m2 Intrathecal Cytarabine Intrathecal Methotreate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation: Vincristine, Mecaptopurine, Intrathecal Methotrexate
Description: Vincristine 1.5mg/m2 Mecaptopurine 50mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 75mg/m2 L-asparaginase 6,000U/m2 Intrathecal Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation: Vincristine, Mecaptopurine, Cyclophosphamide, Cytarabine, L-asparaginase, Intrathecal Methotrexate
Description: Vincristine 1.5mg/m2 Mecaptopurine 50mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 75mg/m2 L-asparaginase 6,000IU/m2 Intrathecal Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation: Vincristine, Mecaptopurine, Cyclophosphamide, Cytarabine, L-asparaginase, Intrathecal Methotrexate
Description: Vincristine 1.5mg/m2 Mecaptopurine 50mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 75mg/m2 L-asparaginase 6,000IU/m2 Intrathecal Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation: Vincristine, Mecaptopurine, Cyclophosphamide, Cytarabine, L-asparaginase, Intrathecal Methotrexate
Description: Vincristine 1.5mg/m2 Mecaptopurine 50mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 75mg/m2 L-asparaginase 6,000IU/m2 Intrathecal Methotrexate
Study: NCT05656560

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinician education
Description: Brief, online education module for primary care clinicians

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinician education
Description: Brief, online education module for primary care clinicians

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinician education
Description: Brief, online education module for primary care clinicians

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical decision support (CDS)-Justification nudge
Description: EHR clinical decision support alerts-clinician rational for high risk polypharmacy
Study: NCT05463172

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: abdominal strengthening exercises
Description: abdominal strengthening exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pelvic floor muscles strengthening exercises
Description: to strengthen pelvic floor muscles
Study: NCT05474872

Intervention type: DEVICE
Intervention: BIS monitoring
Description: The depth of anesthesia will be monitored using Bispectral Index values.
Study: NCT06099366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interim Maintenance(IM): Vincristine, Methotrexate, Intrathecal Methotrexate
Description: Vincristine 1.5mg/m2 Methotrexate 5,000mg/m2 Intrathecal Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interim Maintenance(IM): Vincristine, Methotrexate, Intrathecal Methotrexate
Description: Vincristine 1.5mg/m2 Methotrexate 5,000mg/m2 Intrathecal Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interim Maintenance(IM): Vincristine, Methotrexate, Mercaptopurine, Intrathecal Methotrexate
Description: Vincristine 1.5mg/m2 Methotrexate 5,000mg/m2 Mecaptopurine: 25mg/m2 Intrathecal Methotrexate
Study: NCT04435561

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard physiotherapy rehabilitation and dry needling
Description: The dry needling group receives 6 sessions of dry needling in the spastic muscles of the upper and lower hemiparetic limbs.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard physiotherapy rehabilitation
Description: This group receives their traditional intervention, without dry needling.